Home > Research > Publications & Outputs > Alginate/Chitosan Particle-Based Drug Delivery ...

Electronic data

Links

Text available via DOI:

View graph of relations

Alginate/Chitosan Particle-Based Drug Delivery Systems for Pulmonary Applications

Research output: Contribution to journalJournal articlepeer-review

Published

Standard

Alginate/Chitosan Particle-Based Drug Delivery Systems for Pulmonary Applications. / Hill, Marcus; Twigg, Matthew; Sheridan, Emer; Hardy, John; Elborn, Joseph; Taggart, Clifford; Scott, Christopher; Migaud, Marie.

In: Pharmaceutics, Vol. 11, No. 8, 379, 02.08.2019.

Research output: Contribution to journalJournal articlepeer-review

Harvard

Hill, M, Twigg, M, Sheridan, E, Hardy, J, Elborn, J, Taggart, C, Scott, C & Migaud, M 2019, 'Alginate/Chitosan Particle-Based Drug Delivery Systems for Pulmonary Applications', Pharmaceutics, vol. 11, no. 8, 379. https://doi.org/10.3390/pharmaceutics11080379

APA

Hill, M., Twigg, M., Sheridan, E., Hardy, J., Elborn, J., Taggart, C., Scott, C., & Migaud, M. (2019). Alginate/Chitosan Particle-Based Drug Delivery Systems for Pulmonary Applications. Pharmaceutics, 11(8), [379]. https://doi.org/10.3390/pharmaceutics11080379

Vancouver

Hill M, Twigg M, Sheridan E, Hardy J, Elborn J, Taggart C et al. Alginate/Chitosan Particle-Based Drug Delivery Systems for Pulmonary Applications. Pharmaceutics. 2019 Aug 2;11(8). 379. https://doi.org/10.3390/pharmaceutics11080379

Author

Hill, Marcus ; Twigg, Matthew ; Sheridan, Emer ; Hardy, John ; Elborn, Joseph ; Taggart, Clifford ; Scott, Christopher ; Migaud, Marie. / Alginate/Chitosan Particle-Based Drug Delivery Systems for Pulmonary Applications. In: Pharmaceutics. 2019 ; Vol. 11, No. 8.

Bibtex

@article{e9e72ad845ca4a0082380f1fdc0916d2,
title = "Alginate/Chitosan Particle-Based Drug Delivery Systems for Pulmonary Applications",
abstract = "Cystic fibrosis (CF) is a complex, potentially life-threatening disease that is most effectively treated through the administration of antibiotics (e.g., colistimethate sodium). Chronic infection with Pseudomonas aeruginosa is one of the most significant events in the pathogenesis of cystic fibrosis, and tobramycin is the treatment of choice for those patients with chronic P. aeruginosa infection who are deteriorating despite regular administration of colistimethate sodium. Effective treatment can be challenging due to the accumulation of thickened mucus in the pulmonary environment, and here we describe the results of our investigation into the development of alginate/chitosan particles prepared via precipitation for such environments. Tobramycin loading and release from the alginate/chitosan particles was investigated, with evidence of both uptake and release of sufficient tobramycin to inhibit P. aeruginosa in vitro. Functionalisation of the alginate/chitosan particles with secretory leukocyte protease inhibitor (SLPI) was shown to help inhibit the inflammatory response associated with lung infections (via inhibition of neutrophil elastase activity) and enhance their interaction with cystic fibrosis mucus (assayed via reduction of the depth of particle penetration into the mucus) in vitro, which have prospects to enhance their efficacy in vivo.",
keywords = "biomedical applications, drug delivery systems, particles, antimicrobial",
author = "Marcus Hill and Matthew Twigg and Emer Sheridan and John Hardy and Joseph Elborn and Clifford Taggart and Christopher Scott and Marie Migaud",
year = "2019",
month = aug,
day = "2",
doi = "10.3390/pharmaceutics11080379",
language = "English",
volume = "11",
journal = "Pharmaceutics",
issn = "1424-8247",
publisher = "MDPI - Open Access Publishing",
number = "8",

}

RIS

TY - JOUR

T1 - Alginate/Chitosan Particle-Based Drug Delivery Systems for Pulmonary Applications

AU - Hill, Marcus

AU - Twigg, Matthew

AU - Sheridan, Emer

AU - Hardy, John

AU - Elborn, Joseph

AU - Taggart, Clifford

AU - Scott, Christopher

AU - Migaud, Marie

PY - 2019/8/2

Y1 - 2019/8/2

N2 - Cystic fibrosis (CF) is a complex, potentially life-threatening disease that is most effectively treated through the administration of antibiotics (e.g., colistimethate sodium). Chronic infection with Pseudomonas aeruginosa is one of the most significant events in the pathogenesis of cystic fibrosis, and tobramycin is the treatment of choice for those patients with chronic P. aeruginosa infection who are deteriorating despite regular administration of colistimethate sodium. Effective treatment can be challenging due to the accumulation of thickened mucus in the pulmonary environment, and here we describe the results of our investigation into the development of alginate/chitosan particles prepared via precipitation for such environments. Tobramycin loading and release from the alginate/chitosan particles was investigated, with evidence of both uptake and release of sufficient tobramycin to inhibit P. aeruginosa in vitro. Functionalisation of the alginate/chitosan particles with secretory leukocyte protease inhibitor (SLPI) was shown to help inhibit the inflammatory response associated with lung infections (via inhibition of neutrophil elastase activity) and enhance their interaction with cystic fibrosis mucus (assayed via reduction of the depth of particle penetration into the mucus) in vitro, which have prospects to enhance their efficacy in vivo.

AB - Cystic fibrosis (CF) is a complex, potentially life-threatening disease that is most effectively treated through the administration of antibiotics (e.g., colistimethate sodium). Chronic infection with Pseudomonas aeruginosa is one of the most significant events in the pathogenesis of cystic fibrosis, and tobramycin is the treatment of choice for those patients with chronic P. aeruginosa infection who are deteriorating despite regular administration of colistimethate sodium. Effective treatment can be challenging due to the accumulation of thickened mucus in the pulmonary environment, and here we describe the results of our investigation into the development of alginate/chitosan particles prepared via precipitation for such environments. Tobramycin loading and release from the alginate/chitosan particles was investigated, with evidence of both uptake and release of sufficient tobramycin to inhibit P. aeruginosa in vitro. Functionalisation of the alginate/chitosan particles with secretory leukocyte protease inhibitor (SLPI) was shown to help inhibit the inflammatory response associated with lung infections (via inhibition of neutrophil elastase activity) and enhance their interaction with cystic fibrosis mucus (assayed via reduction of the depth of particle penetration into the mucus) in vitro, which have prospects to enhance their efficacy in vivo.

KW - biomedical applications

KW - drug delivery systems

KW - particles

KW - antimicrobial

U2 - 10.3390/pharmaceutics11080379

DO - 10.3390/pharmaceutics11080379

M3 - Journal article

VL - 11

JO - Pharmaceutics

JF - Pharmaceutics

SN - 1424-8247

IS - 8

M1 - 379

ER -